vs
Side-by-side financial comparison of Biodexa Pharmaceuticals Plc (BDRX) and NOVO NORDISK A S (NVO). Click either name above to swap in a different company.
Biodexa Pharmaceuticals Plc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, including epilepsy and rare neurodegenerative conditions. It operates primarily across European and North American markets, advancing multiple pipeline candidates through clinical trials to address unmet patient needs.
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares.
